-
Human Genome Sciences Reports EPS of $(0.69) vs. $(0.48) Estimate (HGSI)
Thursday, April 28, 2011 - 4:05pm | 18Human Genome Sciences (NASDAQ: HGSI) Reports EPS of $(0.69) vs. $(0.48) Estimate
-
Oncothyreon Announces Proposed Public Offering of Common Stock (ONTY)
Thursday, April 28, 2011 - 4:03pm | 130Oncothyreon Inc. (NASDAQ: ONTY) today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. Oncothyreon also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares...
-
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study (KERX)
Thursday, April 28, 2011 - 4:01pm | 103Keryx Biopharmaceuticals (Nasdaq: KERX) today announced the final dataset from the Phase 3 short-term clinical trial of Zerenex ^™ (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The Zerenex data was presented earlier today at the National...
-
FDA Panel Recommends Vertex's Telaprevir In 18-0 Vote -Bloomberg (VRTX)
Thursday, April 28, 2011 - 3:13pm | 22Bloomberg reports that the FDA panel recommends Vertex's (NASDAQ: VRTX) Telaprevir in 18-0 vote.
-
Companies with CEO Buys of Over 50k Shares in April 2011
Thursday, April 28, 2011 - 1:12pm | 395ParkerVision (NASDAQ: PRKR) ParkerVision, Inc. designs, develops and markets its proprietary RF technologies which enable advanced wireless communications for current and next generation mobile communications networks. Its solutions for wireless transfer of radio frequency (RF) waveforms enable...
-
Short-Term Traders Should Check Out Regeneron (REGN)
Thursday, April 28, 2011 - 11:53am | 100Regeneron Pharmaceuticals (NASDAQ: REGN) has been offering up some terrific day trading opportunities in the last couple of sessions after some positive Phase III data for its drug ZALTRAP for second-line Metastatic Colorectal Cancer. The stock surged around 28% yesterday and has already made...
-
CEL-SCI Commences Phase III Clinical Trial in Head and Neck Cancer in India
Thursday, April 28, 2011 - 11:21am | 145CEL-SCI Corporation (NYSE: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India. Enrollment is...
-
Five Cash-Generating Dividend Stocks to Consider
Thursday, April 28, 2011 - 11:12am | 710American States Water (NYSE: AWR) When it comes to stocks that regularly hand over dividends, few can top the standard set by American States Water. With a regularity that humans can only reach with fiber supplements, American Water pays out a dividend each and every quarter. On Tuesday, the Board...
-
Q&A With Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. Discussing BioSante's Pipeline into 2012
Thursday, April 28, 2011 - 11:05am | 1252Point Roberts WA, LINCOLNSHIRE, Ill. April 28, 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech stocks and pharma stocks, features an exclusive Q&A interview with Mr. Stephen M. Simes, President and Chief Executive...
-
EU Says Cephalon and Teva May Have Hindered Sales of their Generic Drug, EU will Probe Deal (CEPH, TEVA)
Thursday, April 28, 2011 - 11:03am | 33EU says Cephalon (NASDAQ: CEPH) and Teva (NASDAQ: TEVA) may have hindered sales of their generic drug.
-
CEOWORLD top 6 buy Materials stocks list for 28 April- SWC, SSRI, SLW, AAU, ROC, FCX
Thursday, April 28, 2011 - 9:26am | 1144Stillwater Mining Company (NYSE:SWC)- Stillwater Mining Company is engaged in the development, extraction, processing, refining and marketing of palladium, platinum and associated metals (platinum group metals (PGMs)) from a geological formation in south central Montana known as the J-M Reef and...
-
Top five companies Stocks in the Specialty Chemicals industry- ROC, NLC, CYT, FOE, ECL
Thursday, April 28, 2011 - 9:14am | 12001) Rockwood Holdings (NYSE:ROC) ranks first with a gain of 10.09%- The company reported net income of $178 million, or $2.24 a share, for the three months ended March 31. That compares with net income of $36.9 million, or 48 cents a share, in the same quarter last year. The results included a $...
-
Stocks we are watching on 4/28- AMZN, LVLT, NFLX, BIDU, ORCL, YRCW, AMD, GS, POT, FCX, SNDK, IRE, AIB, CIGX, CTIC, AKAM, WFMI
Thursday, April 28, 2011 - 9:09am | 1328Amazon.com Inc. (AMZN) - Amazon.com Inc. (AMZN) broke out above $190 on Wednesday. AMZN will have resistance at $200. Pullbacks below $175 are a buy. Level 3 Communications Inc. (LVLT) - Level 3 Communications Inc. (LVLT) is back above $1.60. Level 3 Communications will have resistance at $1.85....
-
ArQule, Inc. Announces Appointment of Dr. Susan Kelley to Board of Directors (ARQL)
Thursday, April 28, 2011 - 9:01am | 93ArQule, Inc. (Nasdaq: ARQL) today announced the appointment of Susan L. Kelley, M.D. to its board of directors, effective April 27, 2011. Dr. Kelley is currently an independent consultant to the pharmaceutical and biotechnology industries in the field of oncology drug development and strategy....
-
Benchmark Initiates Coverage On Exact Sciences Corporation At Buy, $9 PT
Thursday, April 28, 2011 - 8:56am | 195Benchmark is initiating coverage of Exact Sciences Corporation (NASDAQ: EXAS) with a Buy rating and $9 price target. Exact is developing the Cologuard stool-based DNA test with the intention of being the first non-invasive screening diagnostic that can prevent colorectal cancer by detecting...